Main Article Content


Present study was designed to evaluate effect some synthetic drugs and some herbal compound on Glucose, HbA1c and Systolic and diastolic blood pressure in isoproterenol induced myocardial infarction in normal and Streptozotocin-Nicotinamide induced diabetic in rats. Pioglitazone (10 mg/kg, p.o), Glimepiride (0.5 mg/kg, p.o), Nobivolol (2 mg/kg, p.o), Valsartan (8 mg/kg, p.o) and Hesperidin (100 mg/kg, p.o) were administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and Nicotinamide (12mg/kg, i.p, NIC) and after isoproterenol (200 mg/kg, s.c.) induced myocardial infarction in rats on 29th and 30th day. At the end of experimental period (i.e. on the day 31) serum sample were collected, and glucose, HbA1c were find out and measurement of systolic and diastolic blood pressure. Administration of STZ–NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose and glycosylated hemoglobin (HbA1c) and significant (p<0.01) increased in the level systolic and diastolic blood pressure as compared to respective control groups. Treatment with Pioglitazone, Glimepiride and Hesperidin significantly (P<0.05) decreased HbA1c, glucose, systolic and diastolic blood pressure but treatment with Nobivolol and Valsartan significantly (p<0.01) decreased without change on glucose and HbA1c. This study concluded that Pioglitazone, Glimepiride and Hesperidin may show reduced diabetes marker and systolic and diastolic blood pressure but Nobivolol and Valsartan may show reduced only systolic and diastolic blood pressure on experimentally induced myocardial infarction in type 2 diabetic rats.


Blood pressure Glucose HbA1c Streptozotocin Nicotinamide

Article Details

How to Cite
Jagdish Kakadiya, Jigar Brahmbhatt, & Nehal Shah. (2010). Investigation effect of pioglitazone, glimepiride, nobivolol, valsartan and hes-peridine on glucose, HbA1c and blood pressure in experimentally induced myocardial infarction in type 2 diabetic rats. International Journal of Research in Pharmaceutical Sciences, 1(3), 232-238. Retrieved from